Smart early diagnosis of acute myocardial infarction: a ZIF-based nanofluorescence lateral flow immunoassay for point-of-care detection of cTnI

Abstract

Despite significant progress in the diagnosis of acute myocardial infarction (AMI), its morbidity and mortality rates are still high, indicating the necessity of developing easy-to-use diagnostic tests with timely and reliable point-of-care (POC) detection capability. Aiming to address this need, we introduce here for the first time the development of a fluorescence lateral flow immunoassay (LFIA) based on antibody labeled ZIF-8@BSA Au/Ag nanoclusters for the quantitative detection of cardiac troponin I (cTnI) as the major biomarker of AMI. A portable IoT-enabled optoelectronic reader was also fabricated to quantify the fluorescence signals of the developed LFIA, enabling easy, precise, and smart on-site quantitative analysis of cTnI. The developed smart LFIA demonstrated desirable assay performance for cTn1 in a linear concentration range of 10 pg mL⁻¹ to 150 pg mL⁻¹ with an appropriate sensitivity (with a detection limit of 9 pg mL⁻¹) compared to the enzyme-linked immunosorbent assay (ELISA) and other reported assays. The fascinating results of our developed smart LFIA for easy, rapid (∼10 min), and highly sensitive and specific detection of cTnI in serum and whole blood samples make it a very promising biosensor capable of being exploited for smart, reliable, and early diagnosis of AMI at the POC.